Download PDF
Semin Thromb Hemost 2003; 29(5): 467-472
DOI: 10.1055/s-2003-44554
Copyright © 2003 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Hyperviscosity Syndrome in Plasma Cell Dyscrasias

Jayesh Mehta1,2 , Seema Singhal2
  • 1Professor of Medicine, The Feinberg School of Medicine, The Robert H. Lurie Comprehensive Cancer Center, Northwestern University , Chicago, Illinois
  • 2Multiple Myeloma Program, Division of Hematology/Oncology, The Feinberg School of Medicine, The Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois
Further Information

Publication History

Publication Date:
21 November 2003 (online)

    Permissions and Reprints

ABSTRACT

Hypergammaglobulinemia increases serum viscosity and is the most common cause of hyperviscosity syndrome. Monoclonal hypergammaglobulinemia resulting in hyperviscosity syndrome is seen in multiple myeloma and Waldenström's macroglobulinemia. The reasons for elevated viscosity are increased protein content and large molecular size, abnormal polymerization, and abnormal shape of immunoglobulin molecules. Other hematologic and metabolic abnormalities seen in patients with plasma cell dyscrasias also contribute to hyperviscosity. Symptomatic hyperviscosity is much more common in Waldenström's macroglobulinemia (10 to 30%) than it is in myeloma (2 to 6%). Symptoms of hyperviscosity usually appear when the normal serum viscosity of 1.4 to 1.8 cp reaches 4 to 5 cp, corresponding to a serum immunoglobulin M (IgM) level of at least 3 g/dL, an IgG level of 4 g/dL, and an IgA level of 6 g/dL. Symptoms of hyperviscosity include constitutional symptoms; bleeding; and ocular, neurological, and cardiovascular manifestations. Immediate therapy of symptomatic hyperviscosity is directed at reduction of blood viscosity by plasmapheresis to control symptoms. Long-term management is directed at control of the underlying disease to prevent production of the monoclonal protein. There may be a small proportion of individuals, usually old or with severely compromised performance status, who undergo plasma exchange as the sole symptomatic therapy of hyperviscosity secondary to plasma cell dyscrasia.

KEYWORDS

Hyperviscosity - gammaglobulin - macroglobulinemia - myeloma

REFERENCES

  • 1 Kwaan H C, Bongu A. The hyperviscosity syndromes.  Semin Thromb Hemost . 1999;  25 199-208
    Article in Thieme ConnectPubMedGoogle Scholar
  • 2 Rosenson R S, McCormick A, Uretz E F. Distribution of blood viscosity values and biochemical correlates in healthy adults.  Clin Chem . 1996;  42 1189-1195
    PubMedGoogle Scholar
  • 3 Somer T. Rheology of paraproteinaemias and the plasma hyperviscosity syndrome.  Baillieres Clin Haematol . 1987;  1 695-723
    PubMedGoogle Scholar
  • 4 McGrath M A, Penny R. Paraproteinemia: blood hyperviscosity and clinical manifestations.  J Clin Invest . 1976;  58 1155-1162
    PubMedGoogle Scholar
  • 5 Crawford J, Cox E B, Cohen H J. Evaluation of hyperviscosity in monoclonal gammopathies.  Am J Med . 1985;  79 13-22
    PubMedGoogle Scholar
  • 6 Rajkumar S V, Greipp P R. Plasma cells and immunoglobulins. In: Mehta J, Singhal S, eds. Myeloma London: Martin Dunitz 2002: 3-23
    Google Scholar
  • 7 Roberts-Thomson P J, Mason D Y, MacLennan I C. Relationship between paraprotein polymerization and clinical features in IgA myeloma.  Br J Haematol . 1976;  33 117-130
    PubMedGoogle Scholar
  • 8 Mestecky J, Hammack W J, Kulhavy R, Wright G P, Tomana M. Properties of IgA myeloma proteins isolated from sera of patients with the hyperviscosity syndrome.  J Lab Clin Med . 1977;  89 919-927
    PubMedGoogle Scholar
  • 9 Preston F E, Cooke K B, Foster M E, Winfield D A, Lee D. Myelomatosis and the hyperviscosity syndrome.  Br J Haematol . 1978;  38 517-530
    PubMedGoogle Scholar
  • 10 Chandy K G, Stockley R A, Leonard R C. et al . Relationship between serum viscosity and intravascular IgA polymer concentration in IgA myeloma.  Clin Exp Immunol . 1981;  46 653-661
    PubMedGoogle Scholar
  • 11 MacKenzie M R, Babcock J. Studies of the hyperviscosity syndrome. II. Macroglobulinemia.  J Lab Clin Med . 1975;  85 227-234
    PubMedGoogle Scholar
  • 12 Hall C G, Abraham G N. Size, shape, and hydration of a self-associating human IgG myeloma protein: axial asymmetry as a contributing factor in serum hyperviscosity.  Arch Biochem Biophys . 1984;  233 330-337
    CrossrefPubMedGoogle Scholar
  • 13 Joles J A, Willekes-Koolschijn N, Koomans H A. Hypoalbuminemia causes high blood viscosity by increasing red cell lysophosphatidylcholine.  Kidney Int . 1997;  52 761-770
    PubMedGoogle Scholar
  • 14 Lane D W, L'Anson S. Viscosimetric effect of fibrinogen.  J Clin Pathol . 1994;  47 1004-1005
    PubMedGoogle Scholar
  • 15 Shaver-Lewis M J, Shah S V. The kidney in plasma cell disorders. In: Mehta J, Singhal S, eds. Myeloma London: Martin Dunitz 2002: 203-221
    Google Scholar
  • 16 Reinhart W H, Gaudenz R, Walter R. Acidosis induced by lactate, pyruvate, or HCl increases blood viscosity.  J Crit Care . 2002;  17 68-73
    CrossrefPubMedGoogle Scholar
  • 17 Alkner U, Hansson U B, Lindstrom F D. Factors affecting IgA related hyperviscosity.  Clin Exp Immunol . 1983;  51 617-623
    PubMedGoogle Scholar
  • 18 Lokhorst H. Clinical features and diagnostic criteria. In: Mehta J, Singhal S, eds. Myeloma London: Martin Dunitz 2002: 151-168
    Google Scholar
  • 19 Singh A, Eckardt K U, Zimmermann A. et al . Increased plasma viscosity as a reason for inappropriate erythropoietin formation.  J Clin Invest . 1993;  91 251-256
    CrossrefPubMedGoogle Scholar
  • 20 Russell J A, Powles R L. The relationship between serum viscosity, hypervolaemia and clinical manifestations associated with circulating paraprotein.  Br J Haematol . 1978;  39 163-175
    PubMedGoogle Scholar
  • 21 Dalakas M C. High-dose intravenous immunoglobulin and serum viscosity: risk of precipitating thromboembolic events.  Neurology . 1994;  44 223-226
    CrossrefPubMedGoogle Scholar
  • 22 Kelleher P, Chapel H. Infections: principles of prevention and therapy. In: Mehta J, Singhal S, eds. Myeloma London: Martin Dunitz 2002: 223-239
    Google Scholar
  • 23 Bloch K J, Maki D G. Hyperviscosity syndromes associated with immunoglobulin abnormalities.  Semin Hematol . 1973;  10 113-124
    PubMedGoogle Scholar
  • 24 Tichy M. Viscosity of paraproteinemic sera.  Acta Medica . 1996;  39 41-43
    PubMedGoogle Scholar
  • 25 Reinhart W H, Lutolf O, Nydegger U R, Mahler F, Straub P W. Plasmapheresis for hyperviscosity syndrome in macroglobulinemia Waldenström and multiple myeloma: influence on blood rheology and the microcirculation.  J Lab Clin Med . 1992;  119 69-76
    PubMedGoogle Scholar
  • 26 Riccardi A, Gobbi P G, Ucci G. et al . Changing clinical presentation of multiple myeloma.  Eur J Cancer . 1991;  27 1401-1405
    PubMedGoogle Scholar
  • 27 Preston F E, Cooke K B, Foster M E, Winfield D A, Lee D. Myelomatosis and the hyperviscosity syndrome.  Br J Haematol . 1978;  38 517-530
    PubMedGoogle Scholar
  • 28 Dimopoulos M A. Waldenström's macroglobulinaemia. In: Mehta J, Singhal S, eds. Myeloma London: Martin Dunitz 2002: 465-480
    Google Scholar
  • 29 Garcia-Sanz R, Montoto S, Torrequebrada A. et al . Waldenström macroglobulinaemia: presenting features and outcome in a series with 217 cases.  Br J Haematol . 2001;  115 575-582
    CrossrefPubMedGoogle Scholar
  • 30 Kyrtsonis M C, Vassilakopoulos T P, Angelopoulou M K. et al . Waldenström's macroglobulinemia: clinical course and prognostic factors in 60 patients. Experience from a single hematology unit (Erratum: Ann Hematol 2002;81:124).  Ann Hematol . 2001;  80 722-727
    CrossrefPubMedGoogle Scholar
  • 31 Rosenbaum E H, Thompson H E, Glassberg A B. Priapism and multiple myeloma. Successful treatment with plasmapheresis.  Urology . 1978;  12 201-202
    CrossrefPubMedGoogle Scholar
  • 32 Facon T, Brouillard M, Duhamel A. et al . Prognostic factors in Waldenström's macroglobulinemia: a report of 167 cases.  J Clin Oncol . 1993;  11 1553-1558
    PubMedGoogle Scholar
  • 33 Ludwig H, Fritz E. Supportive therapy. In: Mehta J, Singhal S, eds. Myeloma London: Martin Dunitz 2002: 397-412
    Google Scholar
  • 34 Singhal S, Mehta J. Thalidomide in cancer.  Biomed Pharmacother . 2002;  56 4-12
    CrossrefPubMedGoogle Scholar
  • 35 Hoffkes H G, Heemann U W, Teschendorf C, Uppenkamp M, Philipp T. Hyperviscosity syndrome: efficacy and comparison of plasma exchange by plasma separation and cascade filtration in patients with immunocytoma of Waldenström's type.  Clin Nephrol . 1995;  43 335-338
    PubMedGoogle Scholar
  • 36 Zucchelli P, Pasquali S, Cagnoli L, Ferrari G. Controlled plasma exchange trial in acute renal failure due to multiple myeloma.  Kidney Int . 1988;  33 1175-1180
    PubMedGoogle Scholar